Rinri Therapeutics is a private biotechnology company developing first-in-class cell therapies to restore hearing. Hearing loss affects over 400m people in the world; 90% caused by sensorineural hearing loss (SNHL). There are currently no disease-modifying therapeutics for SNHL patients. Rinri's pioneering technology seeks to reverse SNHL through the regeneration of the damaged sensory cells in the inner ear, the cochlea. Rinri is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, Pioneer Group and the University of Sheffield.
Company Details
- Employees
- 17
- Founded
- -
- Address
- 217 Portobello, Sheffield,south Yorkshire S1 4dp,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- rinri-therapeutics.com
- HQ
- Sheffield, South Yorkshire
Rinri Therapeutics Questions
Rinri Therapeutics's website is rinri-therapeutics.com
Rinri Therapeutics's LinkedIn profile is https://uk.linkedin.com/company/rinri-therapeutics
Rinri Therapeutics has
17 employees.
View email and phone details for 17
employees at Rinri Therapeutics.
Rinri Therapeutics's industry is
Biotechnology Research
Rinri Therapeutics's top competitors are
Resolution Therapeutics,
Neobe Therapeutics,
Quell Therapeutics,
Cell And Gene Therapy Catapult,
Samsara Therapeutics,
Sensorion,
Nanosyrinx,
Spiral Therapeutics,
Blueberry Therapeutics Ltd,
Unicorn Biotechnologies.
Rinri Therapeutics's categories are Biotechnology Research
Rinri Therapeutics's founding year is 2018
